Table 2.
Current fluoroquinolone use* and the hazard of collagen-associated adverse events
| Antibiotic exposure outcome event | Unadjusted HR | 95% CI | Adjusted† HR |
95% CI |
|---|---|---|---|---|
| Fluoroquinolones | ||||
| Tendon rupture | 3.13 | 2.98 to 3.28 | 2.40 | 2.24 to 2.57 |
| Retinal detachment | 1.28 | 0.99 to 1.65 | 1.47 | 1.08 to 2.00 |
| Aortic aneurysm | 2.72 | 2.53 to 2.93 | 2.24 | 2.02 to 2.49 |
| Amoxicillin (negative tracer) | ||||
| Tendon rupture | 1.56 | 1.46 to 1.66 | 1.41 | 1.29 to 1.54 |
| Retinal detachment | 1.44 | 1.14 to 1.81 | 1.47 | 1.08 to 2.00 |
| Aortic aneurysm | 1.74 | 1.59 to 1.90 | 1.50 | 1.32 to 1.70 |
*Patients considered exposed during fluoroquinolone course and for 30 days following treatment.
†Adjusted for baseline characteristics including sex, income quintile, prior hospital admissions, prior physician visits, diabetes mellitus, hypertension, atherosclerosis, chronic kidney disease, chronic obstructive pulmonary disease, hypothyroidism, depression, inflammatory bowel disease, malignancy, liver disease, prior pneumonia, prior urinary tract infection.